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Abstract 
Background: Genetic classification of breast cancer based on the coding mRNA suggests the evolution 
of distinct subtypes. Whether the non-coding genome is altered concordantly with the coding genome 
and the mechanism by which the cell cycle directly controls the non-coding genome is poorly 
understood.  
Methods: Herein, the miRNA signature maintained by endogenous cyclin D1 in human breast cancer 
cells was defined. In order to determine the clinical significance of the cyclin D1-mediated miRNA 
signature, we defined a miRNA expression superset from 459 breast cancer samples. We compared the 
coding and non-coding genome of breast cancer subtypes.  
Results: Hierarchical clustering of human breast cancers defined four distinct miRNA clusters (G1-G4) 
associated with distinguishable relapse-free survival by Kaplan-Meier analysis. The cyclin D1-regulated 
miRNA signature included several oncomirs, was conserved in multiple breast cancer cell lines, was 
associated with the G2 tumor miRNA cluster, ERα+ status, better outcome and activation of the Wnt 
pathway. The coding and non-coding genome were discordant within breast cancer subtypes. Seed 
elements for cyclin D1-regulated miRNA were identified in 63 genes of the Wnt signaling pathway 
including DKK. Cyclin D1 restrained DKK1 via the 3’UTR. In vivo studies using inducible transgenics 
confirmed cyclin D1 induces Wnt-dependent gene expression.  
Conclusion: The non-coding genome defines breast cancer subtypes that are discordant with their 
coding genome subtype suggesting distinct evolutionary drivers within the tumors. Cyclin D1 
orchestrates expression of a miRNA signature that induces Wnt/β-catenin signaling, therefore cyclin D1 
serves both upstream and downstream of Wnt/β-catenin signaling. 
Key words: cyclin D1, miRNA, breast cancer 
Introduction 
The cyclin D1 (CCND1) gene encodes the 
regulatory subunit of a holoenzyme that phosphory-
lates and inactivates the Rb protein to promote DNA 
synthesis [1]. Cyclin D1 is overexpressed in up to 50% 
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of human breast cancers. Cyclin D1 is required for the 
growth of cultured breast cancer cells and is necessary 
for the growth of oncogene-induced breast tumors in 
mice [2, 3]. The prognostic significance of cyclin D1 
expression in human breast cancer epithelial cells has 
been carefully studied and correlates with ERα+ 
breast cancer and better patient outcome [4-6]. The 
common finding of cyclin D1 overexpression in the 
majority of human breast cancers is a consequence of 
gene amplification, reduced degradation or enhanced 
gene expression via oncogenic signals, including Ras, 
ErbB2 and Wnt/β-catenin signaling [7]. In addition, 
cyclin D1 contributes to the phosphorylation of other 
substrates including NRF1 in order to coordinate 
diverse activities within the cell, including the 
inhibition of mitochondrial metabolism and the 
phosphorylation of transcription regulatory factors [8, 
9]. The DNA-bound form of cyclin D1 regulates gene 
expression through the recruitment of transcription 
factors [10, 11] and histone regulatory enzymes, in the 
context of local chromatin [10, 11]. The recruitment of 
histone deacetylase (HDAC1/HDAC3), histone 
acetylase (p300/CBP) and chromatin remodeling 
protein (SUV39, HP1α) [11] contributes to the 
alterations in gene expression of the coding genome 
[12, 13]. Both androgen- [14] and estrogen- [15] 
regulated growth factor gene expressions require 
cyclin D1 in vivo [7]. 
In addition to regulating the coding region, 
cyclin D1 has been shown to regulate non-coding 
miRNA [16]. The miR-17-20 locus is induced by cyclin 
D1, correlating with an association of cyclin D1 in the 
context of local chromatin within the microRNA 
regulatory region [16]. MicroRNAs (miRNAs) are a 
class of endogenous non-coding small RNAs 
participating in diverse biological processes through 
base-pairing to the complementary sequence in the 3’ 
untranslated region (3’ UTR of mRNA). Two 
complementary short RNA molecules are formed 
from stem-loop-stem pre-miRNA by Dicer cleavage, 
but only mature miRNA can integrate into the 
RNA-induced silencing complex (RISC) to regulate 
target mRNA expression. miRNA abundance is 
regulated in response to cellular signaling during cell 
cycle transition and cyclin D1 has been shown to 
govern miRNA processing through the induction of 
Dicer [17]. An alteration in miRNA expression is 
thought to contribute to the timing of cell-cycle 
transition, cell proliferation, stem cell self-renewal, 
cancer onset and progression [18]. An association of 
specific miRNA with initiation, progression and 
therapy resistance in human breast cancer has been 
demonstrated [19, 20]. The molecular mechanisms 
coordinating patterns of miRNA expression are 
poorly understood but are considered important for 
targeted therapies, in particular for therapy-resistant 
breast cancer [19]. In this regard, the let-7 and 
miR-17-20 cluster is induced by estrogen [21] and 
let-7f contributes to aromatase inhibitor resistance 
through repressing the aromatase promoter [22]. The 
miRNA cluster C19MC member miR-519a was 
identified to be the most highly upregulated miRNA 
in tamoxifen-resistant MCF-7 cells [23]. miR-519a 
overexpression increased viability and the S-phase 
population and decreased tamoxifen-induced 
apoptosis [23]. 
The multiple distinct mechanisms regulating the 
Wnt pathway are critical for the fine-tuning of 
signaling that occurs during physiological and 
biological processes. Disruption of these constraining 
influences occurs in human malignancies including 
breast cancer. Activation of the Wnt/β-catenin 
pathway in human breast cancer contributes to 
cellular proliferation, in part through the induction of 
cyclin D1 [24-26]. The canonical Wnt/β-catenin 
pathway is induced by Wnt ligands that bind to 
receptors including Frizzled (Fzd) [27] and the LDL 
receptor-related proteins 5 or 6 (LRP5, LRP6) [28]. The 
cytoplasmic protein Dishevelled (Dvl) is phosphory-
lated and thereby dissociates from a destruction 
complex, which includes AXIN, adenomatous 
polyposis coli (APC), casein kinase 1α (CK1α) and 
glycogen synthase kinase 3β (GSK3β). The stabilized 
β-catenin translocates to the cell nucleus to form a 
transcriptional complex with β-catenin LEF/TCF, 
thereby inducing downstream gene expression. 
Several pathways antagonize β-catenin signaling. The 
Dickkopf WNT signaling pathway inhibitor (DKK) 
proteins are antagonists of the WNT signaling 
pathway. DKKs function by isolating the LRP6 
co-receptor so that it cannot support the WNT 
signaling pathway [29] and via a reduction in 
β-catenin abundance [30]. Although it is known that 
cyclin D1 is a downstream target of Wnt signaling, the 
notion that cyclin D1 functions upstream of Wnt 
signaling remains to be determined [24-26]. 
Given the importance of cyclin D1 in breast 
cancer, the current studies were conducted in order to 
generate a comprehensive analysis of the miRNA 
regulated by endogenous human cyclin D1 in breast 
cancer cells. The cyclin D1-regulated microRNA 
signature was associated with ERα positive breast 
tumors and activation of the Wnt pathway. The cyclin 
D1-mediated miRNA signature engages a network of 
coding genes, including DKK, that govern Wnt 
signaling. Thus in addition to serving as a 
down-stream target of Wnt/β-catenin, cyclin D1 
governs an additional regulatory mechanism that 
activates Wnt via non-coding miRNA. 
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Results  
Cyclin D1 induces oncogenic miRNA 
abundance in breast cancer cell MCF-7. Cyclin D1 is 
overexpressed in up to 50% of human breast cancers 
and was previously shown to regulate miR-17-20 
expression in breast cancer [16]. In order to define a 
comprehensive analysis of the miRNA regulated by 
cyclin D1 in human MCF-7 breast cancer cells, 
quantitative real-time RT-PCR-based miRNA analysis 
was conducted comparing the miRNA expression 
profiles in MCF-7 cells or MCF-7 cells treated with 
cyclin D1 siRNA (Figure 1A, B). Among 742 examined 
miRNAs, ~500 were detectable with ~30% showing 
>1.5-fold reduced expression in cyclin D1 knock-down 
cells (Figure 1C). In contrast, miR-21, the most 
abundant miRNA in MCF-7 cells, was not 
significantly regulated by endogenous cyclin D1. The 
fold change in expression (Cyclin D1+ vs. Cyclin D1-) of 
representative miRNAs is shown in Figure 1D, and 
further confirmed using QRT-PCR as shown in Figure 
1E. The cancer-related miR-17-92 cluster (Figure S1A) 
and its paralogs (Figure S1B, C) were induced by 
endogenous cyclin D1. The Oncomir C19MC cluster 
[31], including miR-517c, 518d, 518c, 518f, 519, 525, 
was also induced by endogenous cyclin D1 (Figure 
S1D). In addition, members of the let-7 miRNA family 
were reduced by cyclin D1a siRNA (Figure S1E, F). In 
order to determine the miRNA signature of cyclin D1 
in other breast cancer cell lines, representative 
miRNAs were analyzed in Hs578t cells (Figure S2). In 
Hs578t cells, 10 of the 15 miRNA were reduced by 
cyclin D1 siRNA, suggesting significant conservation 
of regulatory mechanisms between breast cancer cell 
lines.  
Classification of human breast cancers by their 
miRNA expression profiles. Emerging evidence has 
demonstrated miRNA involvement in human cancers 
including breast cancer [19, 20]. In order to determine 
the functional significance of the cyclin D1-regulated 
miRNA expression profile, a compendium of breast 
tumor miRNA was generated from multiple miRNA 
expression datasets that were associated with clinical 
information (Figure 2A). The compendium consisted 
of 114 miRNAs (Table S1) measured in 459 tumors 
(Figure 2A). Of these, 265 tumors were associated 
with estrogen receptor status, 308 tumors were 
associated with tumor grade, 175 tumors were 
classified using mRNA expression profiles of 
molecular subtypes and 249 tumors were linked with 
time to relapse data. We used this data to classify 
tumors using hierarchical clustering to identify four 
clusters of tumors (referred to as G1-4; Figure 2A) on 
the basis of expression of all miRNAs in the 
compendium. In order to determine the pathological 
significance of miRNA expression profiles, we 
evaluated the association of these miRNA subtypes 
with relapse-free survival (Figure 2B). Kaplan-Meier 
analysis indicated that tumors in groups G1 and G2 
have relatively good prognosis whereas tumors in 
groups G3 and G4 have poor prognosis. In addition, a 
significant difference was detected in the risk of 
relapse between the four groups (p = 0.04). 
Cox-regression analysis verified that tumors in the G4 
group have significantly higher risk of relapse than 
tumors in groups G1 and G2 (Figure 2B). The findings 
suggest that miRNA expression profiles are 
associated with differences in prognosis in breast 
cancer.  
The cyclin D1-regulated miRNA signature 
correlated with ERα positive, low grade tumors and 
better outcome for breast cancer. We investigated the 
clinical significance of the cyclin D1-regulated miRNA 
signature identified in breast cancer cells by 
examining associations with clinical covariates, 
including breast cancer-associated miRNA, ERα 
status, tumor grade and molecular genetic subtype 
(coding genome), and relapse-free survival using the 
breast cancer miRNA compendium. The cyclin D1 
miRNA signature consists of 121 miRNAs (Table S2) 
that are upregulated by 2-fold or more in cyclin D1+ 
vs. cyclin D1- cells (Figure 1). 26 of the cyclin 
D1-regulated miRNA displayed corresponding 
regulation in breast cancer patients (Figure 3A, Figure 
S3 and Figure S4). The cyclin D1-regulated 26 
cancer-associated miRNA signature was assessed for 
clinical covariates. First, we calculated expression of 
the cyclin D1-regulated miRNA signature as the 
average expression of these miRNA in each tumor in 
the compendium. We next sorted the tumors based on 
these expression values. We compared the 
distributions of the cyclin D1 miRNA signature in sets 
of tumors classified by clinical covariates using 
non-parametric statistical testing. Notably, high 
expression of the cyclin D1 miRNA signature was 
associated with the good prognosis cluster G2 (Figure 
3B; p = 3.7×10-7). In contrast, low expression of the 
cyclin D1 miRNA signature was associated with the 
poor prognosis cluster G4 (Figure 3B; p = 9.2×10-3). 
The cyclin D1 miRNA signature was positively 
associated with ERα+-status and negatively associated 
with poor outcome histological grade. The cyclin 
D1-regulated miRNA were expressed at a higher level 
in ERα+ positive relative to ERα- disease (Figure 3C, p 
= 0.03; Figure S5). Similarly, cyclin D1-regulated 
miRNA were downregulated in tumors with high 
histological grade (Figure 3D, p = 0.007; Figure S6). In 
contrast, the association with the molecular genetic 
subtype and the cyclin D1-regulated miRNA 
signature was not statistically significant (Figure 3E, 
Figure S7).  
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Figure 1. Cyclin D1 induces a miRNA signature. (A) Schematic representation of the procedure in which MCF-7 cells were treated with control or cyclin D1 
siRNA knockdown. (B) Western blot analyses showing the decreased level of cyclin D1 by siRNA. (C) The pie chart shows the percentage of miRNA with 
expressions altered by cyclin D1 siRNA and their fold change in abundance. (D) Graphical representation showing the distribution of the log2 (control vs. cyclin D1 
siRNA) of miRNA expression in MCF-7 cells. Shadowing represents the miRNAs reduced (green) and induced (red) more than 1.5-fold by endogenous cyclin D1. (E) 
Validation of representative miRNAs’ expression in MCF-7 cells treated with negative control or cyclin D1 siRNA; the results are shown as mean ± SEM (n=3). 
  
Together, these studies demonstrate that the 
cyclin D1-regulated miRNA signature correlates with 
ERα positive tumors, better tumor grade and better 
prognosis. These findings are consistent with 
observed associations between expression of cyclin 
D1 and clinical covariates in breast cancer. 
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Figure 2. Classification of breast tumors by miRNA expression profiling distinguishes good and poor prognosis tumors. (A) miRNA expression 
profiles and clinical information from the breast cancer compendium. Rows indicate expression of 114 miRNA. Columns indicate expression of miRNA in 459 breast 
tumors compiled from four datasets. Green points represent down-regulation, red points represent up-regulation. Rows and columns were sorted using hierarchical 
clustering with Pearson correlation and average linkage. Hierarchical clustering was used to classify tumors into four groups according to their miRNA expression 
profiles (G1 = green, G2 = orange, G3 = blue, G4 = pink, outliers = black). Column color bars indicate the clinical data associated with each sample. (B) Kaplan-Meier 
plot of relapse-free survival in breast cancer for miRNA subtypes. 
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Figure 3. Expression of the cyclin D1-regulated miRNA signature is associated with biological features and clinical outcomes in breast cancer. 
(A) Venn diagram indicating the number of miRNA in the ‘cyclin D1 signature” (miRNA regulated by cyclin D1), the number of miRNA measured in the breast cancer 
compendium and the intersection of these sets. (B) Distribution of cyclin D1 miRNA signature in breast tumors classified by miRNA subtype. Hashmarks below the 
plot indicate the expression of the cyclin D1-regulated miRNA for each tumor. Color indicates the miRNA subtype of the associated set of tumors. High expression 
of the cyclin D1 miRNA signature is associated with G2 (p = 3.7×10-7). Low expression of the cyclin D1 miRNA signature is associated with G4 (p = 9.2×10-3). (C) 
Cyclin D1-regulated miRNA signature in tumors classified by estrogen receptor (ERα) status. Hashmarks below the plot indicate the expression of the cyclin D1 
miRNA signature for each tumor. Color indicates the estrogen receptor status of the associated set of tumors. High expression of the cyclin D1 miRNA signature is 
associated with ERα-positive disease (p = 0.03). (D) Cyclin D1-regulated miRNA signature in tumors classified by histological grade. Low expression of the cyclin D1 
miRNA signature is associated with grade 3 (p = 0.007). (E). Cyclin D1 miRNA signature in tumors classified by molecular genetic (coding genome) subtype.  
 
The cyclin D1 miRNA signature intersects Wnt 
signaling. In order to investigate further the 
biological significance of the cyclin D1-mediated 
miRNA signature in breast cancer, we performed a 
target gene screening and pathway analysis to the 26 
miRNA signature regulated by endogenous cyclin D1 
in breast cancer. Alignment of the cyclin D1-regulated 
breast cancer-associated miRNA signature with gene 
sequences identified 63 genes in the Wnt pathway 
potentially targeted by the miRNA signature (Figure 
4A). KEGG pathway analysis identified enrichment 
for signaling pathways involved in breast cancer 
regulation including Wnt signaling pathway (p = 
0.048, Figure 4B). The increased DKK1 and decreased 
Wnt5A expression were associated with knockdown 
of cyclin D1 in MCF-7 cells (Figure 4C). Because the 
Wnt signaling inhibitor DKK1 was found to be 
targeted by multiple cyclin D1-regulated miRNAs 
(Figure 4A), a reporter plasmid carrying the 3’UTR of 
DKK1 was applied to cyclin D1-overexpressing cells, 
showing ~20% inhibition of DKK1 by cyclin D1 in 
MCF-7 cells (Figure 4D, E). We hypothesized that 
cyclin D1-regulated miRNAs, including miR-34a and 
miR-148, suppressed DKK1 expression. A comparison 
was therefore made between the DKK1 3’UTR and a 
DKK1 3’UTR reporter with point mutations in the 
miR-34 and miR-148 binding sites, linked to a 
luciferase reporter vector (Figure 4F). Cyclin D1 
siRNA upregulated the DKK1 WT 3’UTR, but did not 
regulate the DKK1 3’UTR that was mutated in the 
miR-34 and miR-148 binding site (Figure 4G). In 
addition, enforced overexpression of miR-34 or 
miR-148a suppressed the DKK1 WT 3’UTR reporter, 
but failed to repress the DKK1 mutated 3’UTR (Figure 
4H, I and Figure S8). Together these studies provide 
further support for a model in which the cyclin 
D1-regulated miRNAs contribute to Wnt signaling 
regulation by cyclin D1 in MCF-7 cells.  
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Figure 4. Cyclin D1-regulated miRNAs govern the Wnt signaling pathway. (A) Interaction between cyclin D1-regulated miRNAs and target mRNAs in the 
Wnt signaling pathway. The y-axis shows Wnt signaling pathway genes that are predicted targets of the cyclin D1-regulated miRNA. The x-axis shows cyclin 
D1-regulated miRNAs in MCF-7 cells. Black boxes indicate predicted interactions between the gene and miRNA. Both axes were ordered using (pseudo-) hierarchical 
clustering. (B) Signaling pathways potentially targeted by cyclin D1-regulated miRNAs (p < 0.05) in MCF-7 cells. (C) Upregulation of DKK1 and downregulation of 
Wnt 5A were associated with cyclin D1 knockdown by siRNA in MCF-7 cells. (D) Schematic representation of the Luciferase reporter carrying DKK1 3’UTR. (E) The 
DKK1 3’UTR activity is suppressed by cyclin D1 in MCF-7 cells. (F) Sequencing alignment indicated that DKK1 3’UTR has binding sites to multiple cyclin D1-regulated 
miRNAs including miR-34 and miR-148a. Point mutations to the binding sites were applied to demonstrate the direct interaction between the 3’UTR of DKK1 and 
miR-34/miR-148a. (G) Luciferase reporter assays indicated that WT DKK1 3’UTR activity was inhibited by endogenous cyclin D1 in MCF-7 cells, but not the mutated 
DKK1 3’UTR. (H, I) Luciferase reporter assays are shown as mean ± SEM (n=3). miR-34 or miR-148a overexpression inhibited WT DKK1 3’UTR activity, but not 
mutated DKK1 3’UTR.  
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Cyclin D1-mediated regulation of the Wnt signal 
transduction pathway was assessed in MCF-7 cells 
using cyclin D1 siRNA, and the surrogate TCF- 
responsive luciferase reporter (TOP-LUC). TOP-LUC 
activity, compared with the TCF-mutant reporter 
(FOP-LUC), was increased 80% by endogenous cyclin 
D1 (Figure 5A). Consistent with the repression of the 
DKK1 3’ UTR by cyclin D1, and the identification of 
binding sites for miR-34 and miR-148 in the DKK1 3’ 
UTR, cyclin D1 was shown to induce these miRNAs in 
MCF-7 cells (Figure 1E and Figure S9). In order to 
determine whether acute induction of cyclin D1 was 
sufficient to induce Wnt-mediated gene expression in 
vivo, transgenic mice were employed. Tetracycline 
was used to induce the cyclin D1 transgene and after 1 
week the mammary glands were harvested. The 
induction of the mammary epithelial cell 
(MEC)-targeted cyclin D1 transgene for one week was 
sufficient to induce Wnt signaling pathway genes 
including Smad, Rock, Fzd and others (Figure 5B). 
Consistent with the DKK reporter studies, induction 
of the cyclin D1 transgene reduced expression of the 
Wnt signaling pathway inhibitors DKKs and Prickle 
(Figure 5B).  
In order to examine the possibility that the 
abundance of cyclin D1 may be negatively correlated 
with DKK1, we examined mRNA expression from the 
TCGA database. Analysis was conducted of 1,085 
breast cancer patients and 291 normal control 
samples. As shown in Figure 5C, upregulation of 
cyclin D1 and Wnt5A and downregulation of DKK1 in 
breast cancer samples were observed compared to 
normal control. In addition, the expression of cyclin 
D1 was positively correlated with Wnt4 and Wnt5A 
but negatively correlated with DKK1 expression in 
breast cancer patients (Figure 5D).  
In order to examine potential mechanisms by 
which cyclin D1 regulated miRNA expression herein, 
we considered two previously characterized 
processes. Firstly, in this regard, cyclin D1 has been 
shown to regulate gene transcription via binding in 
the context of chromatin to either repress or induce 
gene expression [7, 32]. Cyclin D1 has also been 
shown to selectively regulate miRNA expression at 
the transcriptional level through binding to the 
promoter region of miRNAs [14]. ChIP-sequence 
analysis demonstrated that within the cyclin 
D1-regulated miRNA signature, cyclin D1 was 
recruited to the regulatory region of miR-216a, 26b, 
298 and 34a (Figure 6A). A second mechanism by 
which cyclin D1 regulates miRNA involves Dicer. Our 
previous work has demonstrated the cyclin D1 
induction of Dicer promotes miRNA biogenesis [17]. 
In addition to miRNA biogenesis, Dicer itself 
contributes to the regulation of miRNA expression, as 
the Dicer-/- cells have altered expression of specific 
miRNA [33]. We therefore compared the miRNA 
expression profile regulated by Dicer, and the miRNA 
expression profile regulated by cyclin D1. They 
showed similar miRNA expression patterns. The 
miRNA miR-10a, let-7d, miR-34c, miR-193* and 
miR-202, were regulated both by Dicer and by cyclin 
D1 (Figure S10, Table S2).  
Taken together these data show that cyclin D1 
induces expression of miRNA (miR-34 and miR-148a) 
that restrains DKK1 via its 3’ UTR through seed 
elements for miR-34 and miR-148a. Cyclin D1 
regulates miRNA expression either through Dicer or 
through regulating miRNA promoter expression 
(Figure 6B).  
Discussion  
The current studies identified several novel 
findings illustrating an important role of cyclin D1 in 
maintaining the abundance of miRNA that govern 
Wnt signaling. Firstly, we show that cyclin D1 
maintains a specific cluster of miRNA in human 
breast cancer cells. Secondly, we showed that the 
cyclin D1-mediated miRNA expression profile was 
concordant with the direction of expression of ~25% 
of the breast cancer-associated miRNA. Thirdly, this 
miRNA signature had specific biological correlates: 
correlated with ERα+ breast cancer, anti-correlated 
with poor outcome and highly correlated with Wnt 
signaling. Fourthly, the cyclin D1-mediated miRNA 
expression profile correlated highly with a matrix of 
cyclin D1-mediated miRNA identified target 3’ UTR 
sequences in the known Wnt target genes. Evidencing 
the significance of cyclin D1 in Wnt signaling, DKK1, 
a repressor of Wnt signaling, was repressed by 
endogenous cyclin D1, and expression of a cyclin D1 
transgene in the mammary gland of transgenic mice 
induced expression of Wnt-related gene expression.  
Emerging evidence has demonstrated 
interactions between cyclin D1 and miRNAs (miR-17/ 
20, let-7 and miR-15/16) in control of human cancer 
[16, 34, 35]. The current studies demonstrated that 
cyclin D1 enhanced the expression of several 
onco-miRNAs. The miR-17-92 cluster of miRNAs on 
human chromosome 13 and its cluster paralogs 
(miR-106b-25, on chromosome 7) and the 
miR-106a-363 cluster on the X chromosome are 
known to act as oncogenes [36]. The miRNAs induced 
by cyclin D1 included the oncomiR miR-17-20 and all 
of its paralogs [36] (Figure S1). Components of a 
miRNA polycistron (miR-506, 513a, 518f, 519d, 520b 
and 524) [37], which are amplified in tumors [38] and 
contribute to tamoxifen resistance, were induced by 
cyclin D1. It is of interest that every miRNA of the 
oncomiR clusters was induced by cyclin D1. The cyclin 
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D1 gene undergoes alternative splicing, resulting in 
two distinct isoforms encoding alternate carboxyl 
terminus C, with distinct properties in the DNA 
damage response and cell migration [39, 40].  
 
 
Figure 5. Cyclin D1 activated Wnt signaling in the mammary gland in vivo. (A) Schematic representation of the TOP-LUC and Tcf site mutant reporter 
(FOP-Luc). Tcf activity was assessed in MCF-7 cells using the Top-Flash-Luc reporter, with activity shown as mean ± SEM. The assays indicate higher Wnt signaling 
activity in cyclin D1+ MCF-7 cells compared with cyclin D1- MCF-7 cells. (B) Schematic representation of the tetracycline-inducible mammary gland epithelial 
cell-targeted cyclin D1a transgenic mice. Mammary gland mRNA was analyzed after 1 week from three transgenic mice. The expression and p value of Wnt signaling 
pathway genes regulated by the transgene are shown. (C) TCGA analysis showed the upregulation of cyclin D1 and Wnt 5A and downregulation of DKK1 in 1085 
breast cancer patients compared to 291 normal control samples. (D) TCGA analysis showed the positive correlation between cyclin D1 and Wnt 4/Wnt 5A 
expression, and negative correlation between cyclin D1 and DKK1 expression in breast cancer patients. 
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Figure 6. (A) ChIP of cyclin D1 followed by ChIP sequencing (ChIP-Seq) indicated the binding of cyclin D1 on the promoter region of indicated miRNAs that 
were identified within the cyclin D1-regulated miRNA signature. (B) Schematic representation of the mechanisms through which cyclin D1 induces tumorigenesis in 
breast cancer by repression of DKK1 and induction of Wnt signaling, which is at least partly mediated by miRNAs. 
 
The current studies conducted hierarchical 
clustering of miRNA from 459 breast cancers and 
thereby identified 4 distinct types of breast cancer 
with distinct survival outcomes, G1 being favorable 
and G4 associated with poor outcome. A comparison 
between miRNA-based classification and mRNA- 
based classification of the same tumors evidenced 
only moderate overlap with some enrichment of the 
basal mRNA expression subtype amongst the G4 
miRNA subtype. The cyclin D1-mediated miRNA 
signature was correlated with the G2 subtype and 
anti-correlated with the G4 subtype. Together these 
findings suggest independent drivers or independent 
evolution of the miRNA vs. mRNA expression within 
an individual patient’s breast cancer. 
Herein the miRNA induced by cyclin D1 were 
shown to align with the seed sequences in the 3’ UTR 
of essentially all known genes of the Wnt pathway. 
Consistent with cyclin D1 activating the 
Wnt/β-catenin signaling pathway, a surrogate 
measurement of this pathway’s activity in reporter 
gene assays, TCF activity was maintained by 
endogenous cyclin D1 in breast cancer cells. 
Furthermore, acute induction of a cyclin D1 transgene 
induced Wnt activity in vivo as assessed by TCF4 IHC 
in the murine mammary gland. In the current studies, 
cyclin D1-regulated miRNAs were predicted to 
induce a broad array of Wnt-activating components 
(Wnt1, Wnt3a, Wnt5A, Wnt10b, Wnt16, Vangl2, 
SIAH1, PP2A) and restraining components governing 
Wnt repression (Prickle 2, DKK1,2,4). In addition to 
the description of Wnt signaling above, the 
canonical Wnt pathway involves degradation of 
β-catenin by a β-TrCP1-containing E3 ligase, and 
alternative β-catenin degradation mediated by 
SIAH-1 (seven in absentia homolog-1) is responsible 
for the effect of CSN5 on β-catenin signaling [41]. 
Cross-talk occurs with other pathways including the 
PI3K/AKT [42, 43]. Active β-catenin is induced by the 
PI3K pathway and is dependent on the phosphatase 
activity of the protein phosphatase PP2A [43]. ERK 
phosphorylation of GSK3β is induced by IGF and 
TGFβ. ERK phosphorylates GSK3β at the Thr 43 
residue, which primes GSK3β for its subsequent 
phosphorylation at Ser9 by p90RSK, resulting in 
inactivation of GSK3β and upregulation of β-catenin 
[42]. Vangl2, a core component in planar cell polarity, 
forms a Wnt-induced receptor complex with Ror2 to 
sense Wnt dosages [44]. Wnt signaling is retrained by 
DKK, and the 3’ UTR of DKK1 is repressed by cyclin 
D1. Tumor suppression by PTEN and p27KIP1 involves 
restraint of β-catenin activity [45]. Cyclin D1 is a target 
of β−catenin/ TCF signaling [24] and β-catenin is a 
marker of poor prognosis in breast cancer [26]. In 
recent studies, cyclin D1 was shown to induce clusters 
of mRNA that govern Wnt/β-catenin transcriptional 
pathways [46]. Endogenous cyclin D1 en-
hanced Wnt and ES cell gene expression and 
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expanded a prostate stem cell population. In these 
prior studies using chromatin immunoprecipitation 
sequencing, cyclin D1-occupied genes were found to 
govern stem cell expansion and induce their 
transcription. The current studies extend our 
understanding of cyclin D1, known to be a 
downstream target of Wnt/β-catenin signaling, by 
showing cyclin D1-induced miRNA clusters that 
engage the Wnt pathway.  
Methods and Materials 
Transgenic mice. Cyclin D1-/- mice were 
maintained in our lab on a mixed C57B1/6x129/SvJ 
background. The tetracycline-inducible mammary 
epithelial cell-targeted cyclin D1a transgenic mice 
established in the FVB strain (MMTV-rtTA-cyclin D1a 
transgenic mice) were previously described [47]. Eight 
to ten-weeks-old female mice was used for in vivo 
experiments. All mouse experiments were done in 
accordance with the guidelines for the care and use of 
laboratory animals at Thomas Jefferson University.  
Cell culture. MCF-7 and Hs578T cells were 
originally from ATCC and were maintained in our 
laboratory. Cells were cultured in DMEM containing 
penicillin and streptomycin (100 mg of each/L) and 
supplemented with 10% fetal bovine serum (FBS).  
siRNAs and transfection. All siRNAs were from 
Qiagen. The target sequence for cyclin D1 was 
AACAAGCTCAAGTGGAACCTG. The target 
sequence for the negative control siRNA was 
AATTCTCCGAACGTGTCACGT. Lipofectamine 
RNAiMax (Invitrogen) was used to transfect siRNA 
into cells following the manufacturer’s instructions. 
miRNA expression profiling and data analysis. 
Human miRNAs in cyclin D1 siRNA-treated MCF-7 
cells and MCF-7 control cells were profiled in 
triplicate using the Exiqon microRNA Ready-to-Use 
PCR Human panel I+II (Product no:203607) and 
miRCURY LNATM Universal cDNA Synthesis Kit 
(Product no:203300) following the Manufacturer’s 
instructions. miRNA expression measurements were 
estimated using the delta-delta Ct method. The set of 
miRNAs regulated by cyclin D1 was identified using 
a differential expression fold change threshold of 2.0 
for comparison with the miRNA expression database 
in breast tumors. For the target gene prediction and 
pathway analysis, a threshold for significance as 
p<0.05 was applied to the above miRNA set regulated 
by cyclin D1. Predicted gene targets for the miRNAs 
were identified using the miRdbv4.0 (http://mirdb 
.org/miRDB/). These predicted targets were 
compared with the KEGG Wnt signaling pathway 
genes obtained from the KEGG pathway database 
(http://www.genome.jp/kegg/kegg2.html).  
 
Gene reporter assays. The WT and mutated 
DKK1-3’UTR luciferase reporter vectors were created 
in our lab. The TOP-LUC / FOP LUC reporters were 
previously described [25]. For cellular transfection 
with reporter DNA, actively growing cells were 
seeded on 12-well plates at a density of 1×105 
cells/well. The next day, cells were co-transfected 
using lipofectamine 2000 (Invitrogen) with 0.5 µg of 
Luc vector and 0.1 µg of CMV/ß-galactosidase 
plasmid. Twenty-four hours after transfection, 
luciferase activities were measured by AutoLumat 
and normalized with ß-galactosidase.  
Compilation of miRNA expression data across 
platforms. Four datasets of microRNA expression 
profiles of breast tumors linked to corresponding 
clinical data were collected from the ArrayExpress 
database (ArrayExpress Identifiers: E-GEOD-22220, 
E-GEOD-7842, E-GEOD-19783, E-GEOD-15885) [20, 
48-51]. In addition to expression data, sample 
annotation information and array design information 
were obtained in the form of ArrayExpress .sdrf and 
.adf files, respectively. Pre-processed data was used if 
available. If pre-processed data was not available, raw 
data was normalized by: calculating an average value 
for foreground and background intensity of replicate 
spots mapping to the same miRNA, log2 
transformation of foreground and background 
signals, background correction by subtracting the 
background signal from each foreground signal, 
thresholding to set missing expression values to an 
arbitrary low value (0.1), and quantile normalization. 
In order to identify common features across array 
platforms, miRNA probes were mapped to the 
mirbase mature miRNA accession identifier [52]. For 
array platforms annotated with sequence information, 
an exact match of the target sequence to the mirbase 
sequence was used to ensure accurate annotation. 
Array platforms without sequence information were 
incorporated only when the specific release of the 
mirbase database used for platform design was 
reported. For these platforms, miRNA name was used 
for annotation based on the corresponding mirbase 
release. Cross-platform normalization was used to 
estimate and minimize the effects from 
dataset-specific noise. In this process, arrays are 
filtered to obtain expression data associated with the 
phenotype of interest. Following array filtering, 
datasets are transformed from probe set space to 
miRNA space by calculating the median expression 
value of all probes mapping to a given miRNA. Next, 
miRNA are filtered to retain only the miRNA that are 
represented on all array platforms. Array-filtered, 
transformed and miRNA-filtered data is normalized 
across platforms using the XPN algorithm [53] 
implemented with the CONOR package [54] in the R 
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Statistical Environment. Data summarization plots, 
including boxplots, two-dimensional PCA 
projections, and hierarchical clustering were used for 
quality control of cross-platform normalization to 
ensure good mixing of data across platforms.  
Evaluation of clinical relevance of cyclin 
D1-regulated miRNA. The clinical implications of 
cyclin D1-mediated miRNA expression were 
investigated by examining the association between 
cyclin D1-regulated miRNA and clinical covariates. 
Cyclin D1-regulated miRNA were identified as 
described above. A signature of cyclin D1 activity in 
clinical tumor samples was obtained based on the 
expression profile of the cyclin D1-regulated miRNA. 
Expression data was median centered such that tumor 
expression profiles reflected the expression of a given 
miRNA relative to the average expression of the 
miRNA across all tumors. The value of the cyclin 
D1-mediated miRNA expression signature for each 
tumor was determined by calculating the average 
expression of cyclin D1-regulated miRNA in each 
tumor. Tumors were then sorted according to 
expression of the cyclin D1-mediated miRNA 
expression signature and association with clinical 
covariates was tested using non-parametric statistical 
hypothesis testing. Association with relapse-free 
survival was assessed by first classifying tumors on 
the basis of miRNA expression, calculating the 
association of cluster membership with relapse-free 
survival and calculating the association between the 
cyclin D1-mediated miRNA expression signature and 
the miRNA clusters. Clusters were defined using 
hierarchical clustering using Pearson correlation and 
average linkage. The first two major bifurcations of 
the sample dendrogram (excluding two small clusters 
of outliers) were used to identify miRNA clusters. Cox 
proportional hazards analysis was used to associate 
miRNA clusters with relapse-free survival. 
Association of the cyclin D1-mediated miRNA 
expression with miRNA clusters was determined as 
described above.  
TCGA database analysis. The GEPIA web 
server [55] was used to analyze the gene expression 
levels of cyclin D1, DKK1 and Wnt A in 1,085 breast 
cancer patients vs. 291 normal samples from TCGA 
and GTEx databases. The Pearson Correlation 
Coefficient was used to determine the strength of the 
relationship between cyclin D1 and Wnt signaling 
factors. Non-log scale for calculation and log-scale 
axis for visualization were applied.  
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